Hamm v. Rhone-Poulenc Rorer Pharmaceuticals, Inc.

187 F.3d 941, 44 Fed. R. Serv. 3d 1162, 1999 U.S. App. LEXIS 18715, 1999 WL 600440
CourtCourt of Appeals for the Eighth Circuit
DecidedAugust 11, 1999
Docket98-1063
StatusPublished
Cited by173 cases

This text of 187 F.3d 941 (Hamm v. Rhone-Poulenc Rorer Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hamm v. Rhone-Poulenc Rorer Pharmaceuticals, Inc., 187 F.3d 941, 44 Fed. R. Serv. 3d 1162, 1999 U.S. App. LEXIS 18715, 1999 WL 600440 (8th Cir. 1999).

Opinion

McMILLIAN, Circuit Judge.

Appellants are present and former employees of defendant Rhone-Poulenc Rorer Pharmaceuticals, Inc. (RPR), a pharmaceutical company, who are appealing from a final order entered in the United States District Court 1 for the District of Minnesota, granting summary judgment in favor of RPR (and the other defendants) and dismissing their civil Racketeer Influenced and Corrupt Organizations Act (RICO) claims for failure to state a claim and their pendent state claims for lack of subject matter jurisdiction. Hamm v. Rhone-Poulenc Rover Pharmaceutical, Inc., 176 F.R.D. 566 (D.Minn. 1997) (district court order adopting report and recommendation of magistrate judge). 2 For reversal, appellants argue that the district court erred in (1) converting RPR’s Rule 12(b)(6) motion to dismiss into a motion for summary judgment and denying their motion to voluntarily dismiss the action without prejudice and (2) dismissing their civil RICO claims for lack of standing. For the reasons discussed below, we affirm the judgment of the district court.

JURISDICTION

The district court had subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331 (RICO, 18 U.S.C. §§ 1961-1968), 1367(a) (supplemental jurisdiction over state law claims). This court has appellate jurisdic *946 tion pursuant to 28 U.S.C. § 1291. The district court entered its judgment on November 25, 1997, and appellants timely filed a notice of appeal on December 24, 1997, pursuant to Fed. R.App. P. 4(a).

BACKGROUND FACTS

Appellants filed this class action against RPR, their employer and a manufacturer of prescription and over-the-counter drugs, and defendants Robert A. Becker, Inc. (Becker), an advertising agency that also operated under the fictional name Genecom, Dr. Alexander Turpie, a physician and a Canadian citizen, and other defendants, asserting civil RICO claims and related state law claims. In their second amended complaint, appellants alleged that RPR constructively discharged, defamed or retaliated against them because they criticized or refused to participate in RPR’s alleged violations of federal law. Appellants alleged that RPR marketed four pharmaceutical products in an unlawful manner by promoting off-label uses. 3 Once the Food and Drug Administration (FDA) approves a drug, physicians may prescribe the drug for use or in a manner not indicated on its FDA-approved label. However, manufacturers are prohibited from promoting such off-label uses.

Appellants alleged that RPR conspired with Becker, Turpie and unnamed physicians and others to illegally promote the use of RPR products prior to FDA approval or for off-label uses with the intent to defraud hospital administrators, physicians and other medical personnel into prescribing or purchasing RPR products, through the use of the mail, wire communications and facilities of interstate commerce, and that appellants were “unwilling pawns” in the fraudulent scheme. More specifically, appellants alleged that RPR improperly marketed four of its pharmaceutical products by promoting those products for off-label use and by compensating physicians for prescribing those products, in violation of applicable federal law. Appellants alleged that RPR carried out its fraudulent scheme by providing information about off-label use of its products to RPR sales representatives, encouraging RPR sales representatives to solicit physicians who would prescribe RPR products for off-label use, arranging speaking events for physicians who prescribed RPR products for off-label use, setting sales quotas that implicitly included off-label sales of RPR products, using Genecom to pay physicians to serve as speakers, and paying physicians to promote off-label uses of RPR products. Appellants alleged that, when they reported these unlawful off-label promotional activities to RPR legal officials, those officials told them to rewrite promotional event payment requests and to destroy evidence of illegal promotions. According to appellants, RPR conducted these activities through the use of the mail, wire communications and facilities of interstate commerce.

Appellants also alleged that defendants conducted or participated in a pattern of racketeering activity, that is, obtaining money from illegal promotions of RPR products by Genecom. Appellants alleged that defendants sent promotional materials and obtained or paid money through the mail (mail fraud, 18 U.S.C. § 1341), transmitted promotional materials and made false representations by interstate telephonic communications (wire fraud, 18 U.S.C. § 1343), and used the facilities of interstate commerce with the intent to distribute the proceeds gained from illegal kickbacks and payments made to influence the promotion and use of RPR products (18 U.S.C. § 1952).

Appellants claimed no injury or damage to themselves as a result of any of RPR’s allegedly illegal promotional activities; however, they alleged that the intent and purpose of these promotional activities was to defraud hospital administrators, physi *947 cians and other medical personnel by persuading them to prescribe or purchase RPR’s products. Appellants also claimed personal injury because they either criticized or refused to participate in RPR’s fraudulent scheme and as a result were terminated, denied promotion and compensation, lost stock options, and defamed.

Before filing an answer, RPR filed a Rule 12(b)(6) motion to dismiss the first amended complaint on the ground that appellants did not have standing to assert civil RICO claims and failed to properly plead racketeering activity. (Turpie also filed a motion to dismiss.) The parties agreed that all motions to dismiss applied to the second amended complaint and that all rulings would apply to all party defendants. The district court referred the motion to dismiss to a magistrate judge for a report and recommendation pursuant to 28 U.S.C. § 636(b)(1)(B). During oral arguments on the motion to dismiss, the magistrate judge questioned counsel for appellants about the effect, if any, on their civil RICO claims of Bowman v. Western Auto Supply Co., 985 F.2d 383, 385-86 (8th Cir.) (Bowman), cert. denied, 508 U.S. 957, 113 S.Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
187 F.3d 941, 44 Fed. R. Serv. 3d 1162, 1999 U.S. App. LEXIS 18715, 1999 WL 600440, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hamm-v-rhone-poulenc-rorer-pharmaceuticals-inc-ca8-1999.